Gilead Sciences reported Q3 2024 total revenues of $7.5 billion, up 7% year-over-year, driven by higher HIV product sales. Net income attributable to Gilead decreased 43% to $1.3 billion, primarily due to a $1.8 billion IPR&D impairment charge related to Trodelvy for NSCLC. Diluted EPS fell 42% to $1.00.HIV product sales grew 9% to $5.1 billion, led by Biktarvy's 13% increase. Oncology sales rose 6% to $816 million, with Trodelvy up 17%. Veklury (remdesivir) sales increased 9% to $692 million amid higher COVID-19 hospitalizations. R&D expenses decreased 4% to $1.4 billion due to the wind-down of certain clinical studies.Gilead maintained its full-year 2024 guidance. The company ended Q3 with $5.0 billion in cash and equivalents, down from $8.4 billion at 2023 year-end, after completing the $3.9 billion acquisition of CymaBay Therapeutics in March. Gilead continues to invest in its pipeline while returning capital to shareholders through dividends and share repurchases.

Gilead Sciences reported Q3 2024 total revenues of $7.5 billion, up 7% year-over-year, driven by higher HIV product sales. Net income attributable to Gilead decreased 43% to $1.3 billion, primarily due to a $1.8 billion IPR&D impairment charge related to Trodelvy for NSCLC. Diluted EPS fell 42% to $1.00.HIV product sales grew 9% to $5.1 billion, led by Biktarvy's 13% increase. Oncology sales rose 6% to $816 million, with Trodelvy up 17%. Veklury (remdesivir) sales increased 9% to $692 million amid higher COVID-19 hospitalizations. R&D expenses decreased 4% to $1.4 billion due to the wind-down of certain clinical studies.Gilead maintained its full-year 2024 guidance. The company ended Q3 with $5.0 billion in cash and equivalents, down from $8.4 billion at 2023 year-end, after completing the $3.9 billion acquisition of CymaBay Therapeutics in March. Gilead continues to invest in its pipeline while returning capital to shareholders through dividends and share repurchases.